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Abstract 26 
Regulatory B cells (Bregs) suppress and reduce autoimmune pathology. However, given the 27 
variety of Breg subsets their role is still unclear in the pathogenesis of type 1 diabetes. Here 28 
we dissect this fundamental mechanism. We show that natural protection from type 1 29 
diabetes in non-obese diabetic (NOD) mice is associated with increased IL-10-producing B 30 
cells, while NOD mice that develop type 1 diabetes have compromised IL-10 production 31 
from B cells. However, B cells from diabetic mice regain IL-10 function if activated by 32 
innate immune receptor, TLR4, and can suppress insulin-specific CD8 T cells in a dendritic 33 
cell (DC) dependent IL-10-mediated fashion. Suppression of CD8 T cells was reliant on B 34 
cell contact with DCs. This cell contact results in deactivation of DCs, inducing a tolerogenic 35 
state, which in turn can regulate pathogenic CD8 T cells. Our findings emphasise the 36 
importance of DC: Breg interactions during the development of type 1 diabetes. 37 
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Regulatory B cells (Bregs) suppress immune responses and support immune tolerance. Breg 38 
cells mitigate inflammation via production of cytokines such as IL-10, TGFb and IL-35[1-3], 39 
which modulate the response of pathogenic T cells and aid the generation of other regulatory 40 
lymphocyte populations. Bregs can suppress various autoimmune diseases, including models 41 
of experimental autoimmune encephalomyelitis (EAE) and arthritis[4-6]. However, in type 1 42 
diabetes, a dual role for B cells is evident. B cells play a pathological role, as B cell depletion 43 
delayed and protected from diabetes[7-9]. Conversely Bregs can prevent the onset of disease 44 
in the NOD mouse model[2, 10]. B cells stimulated with lipopolysaccharide (LPS) 45 
upregulated FasL expression, increased TGFb secretion and prevented the onset of diabetes 46 
upon adoptive transfer[2]. Furthermore, LPS-stimulated B cells induced CD8 T cell anergy in 47 
a membrane-bound TGFb-dependent manner[11]. Activation of B cells through the B cell 48 
receptor (BCR) can also mediate protection from diabetes in NOD mice, via an IL-10-49 
dependent mechanism[12]. In patients with type 1 diabetes, IL-10-producing B cells are 50 
diminished in peripheral blood, compared to healthy control individuals and autoantibody-51 
positive relatives[13].  52 
Similar to humans, NOD mice develop spontaneous type 1 diabetes. However, in most, if not 53 
all, NOD mouse colonies worldwide, approximately 20% (or more) of NOD mice remain 54 
normoglycemic and ‘protected’ from diabetes despite their genetic predisposition[14]. 55 
However, few studies have been done to uncover the mechanism of this natural protection. It 56 
is suggested that B cells, specifically anergic CD40+IL-10-producing B cells found in the 57 
pancreatic islets of long term normoglycemic mice (protected)[13], may confer this natural 58 
protection. However, given the heterogeneity of regulatory B cells[15], which can be induced 59 
via stimulation with both TLR agonists or anti-CD40 we suggest that the mechanism by 60 
which B cells induce natural protection still remains unanswered. 61 
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Here we report that B cells from NOD mice, that have developed diabetes, have lost the 62 
capacity to produce IL-10, whereas B cells from naturally protected NOD animals have 63 
enhanced frequency of IL-10 producing B cells, regardless of the mode of B cell activation. 64 
However, if B cells from diabetic NOD mice receive signalling through innate immune 65 
receptor TLR4, they regain IL-10-producing function and are able to suppress insulin-66 
specific CD8 T cells. For B cells to exert this suppression, contact with dendritic cells (DCs) 67 
is required and is mediated via IL-10. Direct B cell-DC interaction deactivates mature 68 
conventional DCs and promotes an IL-10 dependent tolerogenic DC population. 69 
Results   70 
Altered B cell function in NOD mice with type 1 diabetes 71 
To determine the features of B cells in NOD mice that are “naturally protected” (not diabetic 72 
by 30 weeks of age and hereafter referred to as protected, as these mice rarely develop 73 
diabetes after 30 weeks), we compared B cell responses, from protected or diabetic NOD 74 
mice, to various stimuli. B cells were stimulated through adaptive immune co-stimulatory 75 
pathways (anti-CD40, BCD40) and through innate immune pathways by microbial products 76 
(LPS - BLPS or CpG - BCPG)[16-18]. Unstimulated B cells (BUS) were used as controls (Fig. 77 
1). All stimuli up-regulated B cell activation markers, although the up-regulation of MHC I 78 
and II was not statistically significant, when compared to BUS. Key differences in surface 79 
markers, between B cells from protected and diabetic NOD mice, were that splenic B cells 80 
isolated from protected NOD mice had a lower expression of MHC I and a significantly 81 
lower frequency of CD86-expressing B cells, compared to B cells from diabetic mice (Fig. 82 
1a). In both protected and diabetic NOD mice, the up-regulation of CD80 was evident, 83 
particularly after stimulation with anti-CD40 stimulation, compared to BUS (p<0.001), 84 
whereas we observed that up-regulation of CD86 was greatest if stimulated by LPS 85 
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(p<0.001). Interestingly, the innate immune stimuli, LPS (TLR4) and CPG (TLR9) resulted 86 
in higher up-regulation of PD-L1 expression on B cells (p<0.05 and p<0.001, respectively) 87 
compared to BUS. We observed that after anti-CD40 stimulation (BCD40), a classical B cell 88 
stimulator of adaptive immunity, PD-L1 expression was similar to the unstimulated controls 89 
(Fig. 1a). However, no difference in PD-L1 expression was found between protected and 90 
diabetic NOD mice, corroborating previous literature [19]. 91 
Next, we determined cytokine-production from B cells, activated by the different types of 92 
stimuli. Firstly, intracytoplasmic staining revealed significant induction of IL-10 in splenic B 93 
cells from both protected and diabetic NOD mice following activation with the innate 94 
immune stimuli, LPS and CPG (p<0.05), but not with anti-CD40, the adaptive immune 95 
stimulator, compared to BUS (Fig. 1b, c). However, a much higher proportion of B cells from 96 
protected NOD mice expressed intracellular IL-10, in comparison to the diabetic NOD mice, 97 
even without stimulation (BUS) ex vivo (Fig. 1c, top graph). In particular, there were 98 
considerably lower proportions of IL-10-expressing B cells from diabetic NOD mice when 99 
stimulated with anti-CD40 (Fig.1c; top graph). B cell secretion of IL-10 was only observed 100 
with LPS and CPG stimulation, but not anti-CD40 (Fig. 1c; bottom graph), corroborating 101 
previous literature[16]. Surprisingly, B cells from diabetic NOD mice secreted significantly 102 
more IL-10, although only when stimulated with CPG, compared to B cells from protected 103 
NOD animals (Fig. 1c, bottom graph; p<0.01). IL-10 secretion from LPS-stimulated B cells 104 
was modestly increased in diabetic NOD mice, compared to equivalently stimulated 105 
protected NOD mice, although this difference was not statistically significant (ns). To 106 
address whether the greater proportion of IL-10-producing B cells in protected mice was age 107 
related, but to circumvent the technical challenge that there are no diabetic NOD mice over 108 
30 weeks of age, we investigated B6g7 congenic mice, which have the same MHC haplotype 109 
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but are not prone to diabetes (Sup. Fig. 1). B6g7 mice, aged >35-week-old, have little IL-10 110 
production, indicating that potential for IL-10 production was not likely to be age associated.  111 
Only CPG stimulation promoted IL-6-producing B cells from both protected and diabetic 112 
mice (Fig. 1d), and no statistical difference between protected and diabetic NOD mice was 113 
observed in either intracytoplasmic or secreted IL-6 (Fig. 1d), indicating that diabetes 114 
protection was not related to a lack of pro-inflammatory cytokines in B cells.  115 
These data demonstrated that B cells from diabetic NOD mice are more activated compared 116 
to mice protected from diabetes, particularly in CD86 expression (Fig. 1a, 4rd row). 117 
Furthermore, B cells from diabetic mice show a loss of overall intracellular IL-10 production, 118 
but can regain this function if stimulated via TLR4 or TLR9, highlighted by IL-10 secretion. 119 
Strikingly, when B cells are stimulated with anti-CD40, only protected mice have the 120 
potential to produce cytoplasmic IL-10.  121 
LPS-stimulated B cells suppress antigen-specific CD8 T cells in the presence of DCs  122 
We next investigated whether B cells from diabetic and protected NOD mice could regulate 123 
antigen-specific CD8 T cells via both innate and adaptive signalling. B cells were co-cultured 124 
with insulin-specific CD8 T cells from TCR transgenic G9Ca-/- mice[20] in the presence of 125 
BM-DCs from NOD.PI2tg mice, which express proinsulin (driven by the MHC class II 126 
promoter) in antigen-presenting cells (experimental scheme shown in Fig. 2a). This culture 127 
allowed intrinsic antigen-specific presentation, by proinsulin-expressing DCs, to insulin-128 
specific CD8 T cells, without exogenous antigen. Considering that NOD.PI2tg DCs express 129 
proinsulin, they should be targeted by CD8 T cells from G9Ca-/- mice. Indeed, DC viability 130 
was significantly diminished in the control CD8 and DC culture (without B cells) (Fig. 2b). 131 
The addition of B cells prevented DCs from being killed by CD8 T cells (Fig. 2b) and 132 
importantly, stimulated B cells (BLPS, BCD40, BCPG) promoted more DC survival compared to 133 
unstimulated B cells (BUS) (Fig. 2b). Next, we examined the proliferative function of CD8 T 134 
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cells in response to the intrinsic antigen presented by DCs in a CFSE dilution assay in the 135 
presence of B cells, unstimulated or stimulated, from protected and diabetic animals (Fig. 2c, 136 
d, e). CD8 T cell proliferation was significantly suppressed in the presence of LPS-stimulated 137 
B cells (BLPS), compared to unstimulated B cell (BUS) cultures (p<0.05; Fig. 2c, d, e). 138 
Interestingly, no suppression by B cells, from either protected or diabetic NOD mice, was 139 
observed when activated by other stimuli (Fig. 2c, d, e). Control CD8 T cell proliferation 140 
(CD8+DC alone) is shown in supplementary figure 2a. Similarly, we observed less CD44 141 
expression (Fig. 2f, g) and less MIP1b, the early chemokine produced by activated CD8 T 142 
cells, in the culture supernatant in the presence of BLPS (Fig. 2h). To confirm that CD8 T cell 143 
proliferation was impaired in BLPS cultures, and not due to increased CD8 T cell death, we 144 
assessed CD8 T cell viability and determined that there was no statistical difference between 145 
cultures (Sup. Fig. 2b). 146 
To verify that the suppression by BLPS was TLR4 dependent, we used BLPS from TLR4-/- mice 147 
in the culture system and we observed no suppression of CD8 T cell proliferation or 148 
activation (Fig. 2i), confirming that LPS-mediated suppression was TLR4 dependent. To 149 
probe the direct effect of LPS-stimulated B cells on CD8 T cells, we stimulated G9Ca-/- CD8 150 
T cells with plate-bound anti-CD3/28 and assessed CD8 T cell proliferation in the presence 151 
of B cells with or without stimulation. In contrast to the DC-stimulated T cells (Fig.2d), we 152 
did not observe suppression of the anti-CD3/28 stimulated CD8 T cells by LPS-stimulated B 153 
cells (BLPS) (Fig. 2j). Taken together, our results suggest that the regulation of LPS-activated 154 
B cells on antigen-specific CD8 T cells requires the presence of DCs and importantly B cells 155 
from diabetic mice also have the ability to impair CD8 T cell responses, if stimulated via 156 
TLR4.  157 
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IL-10 mediates CD8 T cell suppression  158 
To investigate the IL-10 contribution to CD8 T cell suppression by LPS-stimulated B cells, 159 
we measured the secreted IL-10 in culture supernatants of the experiments in Fig. 2. BLPS, 160 
from both protected and diabetic mice, had significantly increased IL-10 secretion compared 161 
to BUS (Fig. 3a). Interestingly, when LPS-stimulated B cells from aged B6g7 transgenic mice 162 
(>35 weeks old) were used in our in vitro culture system we neither observed significant CD8 163 
T cell suppression (Sup. Fig. 3a), nor did we find significant IL-10 production (Sup. Fig. 3b), 164 
demonstrating that IL-10 mediates suppression. Furthermore, the addition of LPS-stimulated 165 
NOD B cells had no obvious effect on the secretion of IL-6 (Sup. Fig. 3c), suggesting that 166 
lower levels of IL-6 from protected NOD mice were not responsible for suppression of CD8 167 
T cell proliferation.  168 
To identify the contribution of IL-10 from DCs in our culture system, we analysed secreted 169 
IL-10 from the cultures performed in the presence or absence of DCs (Fig. 3b). We found a 170 
significant increase in the amount of IL-10 secreted when B cells were added to DC+CD8 T 171 
cell cultures, regardless of whether the added B cells were unstimulated or stimulated, from 172 
both protected and diabetic mice. However, the greatest amount of secreted IL-10 was found 173 
in BLPS cultures. Cultures of CD8-DC alone were found to have minimal secreted IL-10 174 
(average 124±25.4pg/ml), suggesting that upon the addition of B cells, either DCs or B cells, 175 
or both, contributed to the augmented IL-10 produced. To further address this finding, B cells 176 
(BUS, BLPS and BCD40) from protected, diabetic or IL-10KO NOD mice were cultured with 177 
either BM-DCs from NOD.PI2tg or BM-DCs from IL-10KO NOD mice (Fig. 3c). IL-10 178 
production in B cell+DC cultures was dependent on B cells capable of producing IL-10, as 179 
only a small amount IL-10 was observed when IL-10KO B cells were cultured with 180 
NOD.PI2tg BM-DCs (Fig.3c). Analysis of the reduced amount of IL-10 produced in IL-181 
10KO cultures revealed no statistically significant difference between NOD.PI2tg BM-DCs 182 
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cultured without B cells, and IL-10KO B cell cultures (Sup. Fig 4a). Furthermore, equivalent 183 
amounts of IL-10 were produced when B cells from protected and diabetic NOD mice were 184 
cultured with IL-10KO BM-DCs (Fig. 3c), indicating that the IL-10 augmentation observed 185 
upon the addition of B cells, is independent of IL-10 from BM-DCs.  186 
As the secreted IL-10 contributed to the suppression of CD8 T cell proliferation, we 187 
evaluated the effect of recombinant IL-10. Surprisingly, increasing concentrations of 188 
recombinant IL-10 alone had little effect on G9Ca-/- CD8 T cell proliferation when cultured 189 
with NOD.PI2tg DCs (Sup. Fig. 4b). Moreover, blocking the IL-10 receptor (anti-IL-10R) 190 
also had little effect on both CD8 T cell proliferation (Sup. Fig.4c, left) and CD44 expression 191 
on CD8 T cells (Sup. Fig. 4c, right). Yet, when BLPS cells were present in the CD8-DC 192 
culture system, adding anti-IL-10R not only reduced suppression of CD8 T cell proliferation 193 
(Fig. 3d), compared to BUS, but also promoted a significant increase of CD44 surface 194 
expression on CD8 T cells (Fig. 3e), compared to control. This was confirmed using B cells 195 
from IL-10KO mice (Fig. 3d, e). In keeping with published reports[21, 22], IL-10 reduced the 196 
expression of co-stimulatory molecules on DCs to exert immunosuppression (Sup. Fig. 4d). 197 
We also found that the significant reduction of CD80 on mature DCs in BLPS cultures, was 198 
reversed by the addition of anti-IL-10R or using B cells from IL-10KO mice (Fig. 3f). 199 
However, CD86 expression on DCs was less affected by the addition of anti-IL-10R or the 200 
use of IL-10KO B cells (Sup. Fig. 4e). Our results, thus far, indicated that IL-10 produced by 201 
LPS stimulated B cells down-regulated CD80 expression on DCs and suppressed antigen-202 
specific CD8 T cells. 203 
 10 
Insulin-specific CD8 T cell suppression is DC-B cell contact dependent 204 
To determine if cell contact is also required for BLPS -mediated CD8 T cell suppression, we 205 
used a transwell culture system. CD8-DC cultures were either in cell contact (cont) or 206 
separated (trans) from B cells, which were unstimulated, or stimulated with LPS (BLPS) or 207 
anti-CD40 (BCD40) (Fig. 4a). Our results revealed that G9Ca-/- CD8 T cell proliferation and 208 
the expression of CD44+ on the CD8 T cells were significantly suppressed when BLPS from 209 
both protected and diabetic NOD mice were in contact with CD8:DCs. This suppression was 210 
significantly reduced when the B cells were separated from CD8:DC cultures (Trans) (Fig. 211 
4a, b). 212 
B cell: DC cell contact synergises cytokine production 213 
Since we observed that CD8 T cell suppression was mediated via both IL-10 and contact 214 
dependent mechanisms, we sought to determine whether cytokine production was B cell: DC 215 
contact dependent. We measured cytokine secretion when B cells were either in contact with 216 
mature NOD.PI2tg BM-DCs, or cultured in transwells, in the presence (Fig. 4c, e) or absence 217 
of T cells (Fig. 4d, f). Firstly, we found that IFNg production was unchanged by the addition 218 
of B cells from either protected and diabetic NOD mice, when not in direct contact (Trans) 219 
with CD8 T cells and DCs, compared to contact cultures (Cont) (Fig. 4c). However, in the 220 
absence of CD8 T cells, B cells from diabetic NOD mice, in direct contact with DCs, induced 221 
more IFNg compared to B cells from protected NOD mice (p<0.01), regardless of the type of 222 
stimulus (Fig.4d). Furthermore, IFNg production was significantly increased when B cells 223 
were stimulated by anti-CD40 (BCD40) (protected; p<0.05, diabetic; p<0.001), which was also 224 
contact dependent (Fig. 4d). 225 
Secondly, we found increased IL-10 in both BLPS protected and diabetic cultures, in the 226 
presence or absence of CD8 T cells, whereas we observed considerably less IL-10 in BLPS 227 
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transwell cultures (Fig. 4e, f). Interestingly, we observed IL-10 production in BLPS cultures 228 
was greater in diabetic NOD mice, compared to protected NOD mice, in the presence of CD8 229 
T cells (Fig. 4e). In contrast, in the absence of CD8 T cells, BLPS cultures in protected NOD 230 
mice had the greatest levels of IL-10 (Fig. 4f). Of note, we observed no differences in IL-231 
12p70 or IL-6 production comparing B cell contact or transwell cultures, indicating they were 232 
not affected by direct B cell contact (data not shown). Taken together, our data suggest that 233 
CD8 T cell suppression is mediated via IL-10 secretion, which is dependent on direct contact 234 
between LPS-stimulated B cells and mature BM-DCs.  235 
BLPS condition mature BM-DCs 236 
We next investigated if B cells induced tolerance in mature BM-DC. Firstly, we co-cultured 237 
B cells with BM-DCs from NOD.PI2tg mice for 3 days. The B cells were then removed, and 238 
the conditioned BM-DCs were washed and co-cultured with G9Ca-/- CD8 T cells for 3 days 239 
(scheme shown in Fig. 5a), before being assessed for proliferation (Fig. 5b) and activation of 240 
CD8 T cells (Fig. 5c), as well as cytokine production from DC:CD8 T cell cultures (Fig. 5d). 241 
Overall, CD8 T cell proliferation (CFSE dilution) and activation (assessed by CD44 surface 242 
expression) was reduced when mature NOD.PI2tg BM-DCs had been exposed to B cells, 243 
regardless of stimulation; however only BLPS, from both protected and diabetic NOD mice, 244 
significantly suppressed insulin-specific CD8 T cells, compared to control (no B cell 245 
exposure).(Fig. 5b). Following pre-exposure to B cells, stimulated with LPS or anti-CD40, 246 
the BM-DCs from DC:CD8 cultures secreted IL-10 (Fig. 5d, left). However, only LPS-247 
stimulated B cells reduced pro-inflammatory cytokine secretion, IL-12p70 (Fig. 5d, middle) 248 
and IL-6 (Fig. 5d, right), by mature BM-DCs.   249 
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B cells modulate activation of mature conventional DCs  250 
We have shown, thus far, that LPS B cells suppress CD8 T cell function, mediated via IL-10, 251 
which is dependent on DC-B cell contact. Considering the importance of B cell: DC contact, 252 
we determined how B cells affect the activation of mature NOD.PI2tg BM-DCs, in the 253 
absence of T cells. We found that all B cells significantly increased survival of DCs in co-254 
cultures (Sup. Fig. 5a); however, B cells from protected NOD mice were more effective at 255 
enhancing DC survival, compared to B cells from diabetic NOD mice (Sup. Fig. 5a). In 256 
protected NOD mice, B cell contact was required for complete DC deactivation, as we found 257 
that MHC I, CD80, CD86 and CD69 were all significantly downregulated on matured BM-258 
DCs when cultured in contact (Cont) with LPS-stimulated B cells, compared with 259 
unstimulated B cells (Fig. 6a, b). B cells from protected NOD mice, when not in direct 260 
contact with DCs (Trans), were less effective in deactivating BM-DCs, with reduced down-261 
regulation of CD86 and CD69 (Fig. 6a, b). Our data suggest that B cells from protected mice 262 
suppress MHC I and CD80 expression on BM-DCs via soluble factors, whereas the 263 
suppression of CD86 and CD69 is mediated via contact mechanisms.  264 
When investigating B cells from diabetic NOD mice, BLPS also downregulated all measured 265 
activation markers on DCs if in direct contact (Cont) (Fig. 6a, b). In contrast, when the same 266 
B cells were separated (Trans) from DCs, we observed minimal effects on mature BM-DCs. 267 
Interestingly, supernatants taken from B cells, which had been stimulated in culture with the 268 
various stimuli (Sup), had no effect on activation of BM-DCs, compared to the DC controls 269 
(dotted line, Fig. 6a, b). However, in BLPS transwell cultures from protected mice, MHC I, 270 
CD80 and CD69 on BM-DCs were still significantly reduced compared to BLPS supernatants 271 
but this effect was not observed in the diabetic B cell transwell cultures (Fig. 6a, b). This 272 
suggests that B cells from protected mice can respond to BM-DCs, in turn deactivating BM-273 
DCs. Conversely, in B cells from diabetic mice this function is absent. Therefore, B cells 274 
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from diabetic mice are less effective in mediating deactivation of mature BM-DCs, but can 275 
regain some of this function if stimulated via TLR4 and have direct contact with BM-DCs.  276 
Of note, B cells from protected and diabetic NOD mice, stimulated via TLR4 or CD40 277 
interaction also significantly downregulated MHC II (Sup. Fig. 5b, c), independent of cell 278 
contact. Collectively, these results reveal that ‘deactivation’ of mature conventional BM-DCs 279 
by B cells requires both direct contact and soluble mediators; with MHC I, II and CD80 more 280 
affected by soluble factors (most likely, cytokines) whereas CD86 and CD69 are more 281 
dependent on direct cell contact. Furthermore, B cells that received signalling via TLR4 are 282 
more efficient in BM-DC ‘deactivation’ and B cells from protected NOD mice are most 283 
effective in this process. 284 
BLPS induce CD45RB+CD11clow tolerogenic BM-DCs 285 
To determine if LPS stimulated B cells not only deactivated mature BM-DCs but induced a 286 
tolerogenic DC population, we cultured B cells and NOD.PI2tg BM-DCs and evaluated 287 
different tolerogenic surface markers (Fig. 7). We demonstrated that BLPS cells, from both 288 
protected and diabetic NOD mice, significantly induced a subset of CD45RB+ DCs compared 289 
with DCs either cultured alone or with BUS (Fig. 7a). However, BLPS from protected NOD 290 
mice induced significantly more CD45RB+ DCs compared to BLPS from diabetic NOD mice 291 
(p<0.05). Interestingly, B cells from diabetic mice stimulated with anti-CD40 (BCD40), also 292 
induced a CD45RB+ population. Furthermore, the induction of CD45RB+ DCs was dependent 293 
on B cell production of IL-10, as neither BLPS and BCD40 from IL-10KO mice induced 294 
CD45RB on BM-DCs (Fig. 7a). Similarly, the addition of B cells from B6G7 mice, which 295 
have fewer IL-10 producing B cells, had no effect on the induction of CD45RB on BM-DCs 296 
(data not shown). 297 
This population of CD45RB+ BM-DCs had a lower expression of CD11c compared to the 298 
CD45RB- counterpart (Fig. 7b, c), a phenotype associated with regulatory DCs[23, 24]. 299 
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Furthermore, significantly fewer CD45RB+ BM-DCs had CD80 or CD86 expression (Fig. 7b, 300 
c), compared to CD45RB- BM-DCs. No difference in CD45RB+ phenotype was observed 301 
between protected and diabetic cultures, therefore overall phenotype is shown (Fig. 7b, c). 302 
We also investigated the expression of PD-L1 or ILT3 on BM-DCs with or without B cell 303 
contact and did not find obvious differences (data not shown), indicating that tolerogenic 304 
DCs induced by B cells in this study do not function through the inhibitory markers PD-L1 or 305 
ILT3 [25, 26].306 
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Discussion 307 
We have several novel findings in this study. Firstly, we report that B cells from NOD mice, 308 
that are naturally protected from diabetes, have increased IL-10-expressing B cells, while B 309 
cells from non-protected diabetic NOD mice show an altered IL-10 profile (Fig. 8 parts 1, 2). 310 
Secondly, we find that TLR4-activated B cells amplify their IL-10 production in response to 311 
contact with mature BM-DC, in turn inducing a DC tolerogenic state, which can suppress 312 
pathogenic CD8 T cells (Fig. 8, part 3). Thirdly, B cells from diabetic NOD mice have a 313 
diminished response to BM-DCs (Fig 8, part 4); however, they regain IL-10 production and 314 
the function of suppressing insulin-specific CD8 T cells, when in the presence of 315 
proinflammatory cytokines and stimulated via TLR4  (Fig. 8, part 5). Lastly, we show that B 316 
cells deactivate mature BM-DCs, via both soluble mediators and cell contact mechanisms.  317 
IL-10-producing B cells (B10) restrain inflammatory responses and it has been widely 318 
documented that B10 cells can negatively regulate autoimmune disease. Furthermore, it is 319 
implied that IL-10-producing B cells are lost in patients with type 1 diabetes, compared to 320 
healthy control individuals[13]. Notably, B10 cells can be induced through both adaptive 321 
(anti-CD40) and innate TLR signalling[16], regulated via different mechanisms[2, 27, 28] 322 
under various inflammatory conditions. Our results reveal a loss in cytoplasmic IL-10 in non-323 
protected diabetic NOD mice, specifically when stimulated via CD40. In line with this, 324 
patients with systemic lupus erythematosus (SLE) have impaired CD19+CD24hiCD38hi Breg 325 
populations that are refractory to CD40 stimulation compared to healthy controls[29]. This 326 
was associated with a lack of STAT-3 phosphorylation after CD40 engagement and not 327 
altered expression of CD40[29]. There was no difference in CD40 expression on splenic B 328 
cells from either protected or diabetic mice in our study (data not shown) as well as in the 329 
studies of others[13]. The lack of IL-10 response with anti-CD40 stimulation could be due to 330 
other factors. These other factors include retention of IL-10 by B cells from protected mice, 331 
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or B cells that respond to CD40 stimulation have trafficked out of the spleen, or the B cells 332 
have been destroyed in vitro after stimulation (however no difference was observed in B cell 333 
viability) or in vivo by other cell types such as FasL+CD5+ B cells[30]. Altogether, our 334 
current results add to the concept that there is a strong association between CD40 stimulation 335 
and the immune regulation of autoimmune disease[4, 31].  336 
Importantly, our study shows, for the first time, that the impaired IL-10 response by B cells in 337 
diabetic NOD mice can be restored when activated via TLR4 or TLR9 signalling. Under 338 
these circumstances, secreted IL-10 from B cells in diabetic NOD mice was increased 339 
compared to B cells from protected mice stimulated with CPG, and to a lesser extent LPS. 340 
Considering that we find B cells from diabetic mice are more activated, it is possible these 341 
cells are primed to secrete cytokines more rapidly. Although others have reported that LPS-342 
stimulated B cells from very young NOD mice exert regulatory effects in type 1 diabetes via 343 
secreted TGFb[2]; however, we did not detect any TGFb secretion in our assays (data not 344 
shown). This disparity may be due to the differences in the age of mice studied.  345 
We demonstrate, in this study, that NOD B cells can deactivate mature BM-DCs, via both 346 
soluble mediators and cell-contact mechanisms. TLR4-stimulated B cells, which produce 347 
more IL-10, exhibit a stronger capacity to deactivate BM-DCs; specifically, the expression of 348 
MHC I, MHC II and CD80 on BM-DCs is clearly reduced. Furthermore, the expression of 349 
CD86 and CD69 are down-regulated by direct B cell: DC contact. Importantly, B cells from 350 
diabetic NOD mice, stimulated via anti-CD40, are not as effective in deactivation of DCs as 351 
B cells from diabetes-protected mice. This could be, in part, due to the increased secretion of 352 
IFNg upon B cell-DC contact in diabetic NOD mice. In addition, we found that BM-DCs 353 
exposed to LPS-stimulated B cells produced less IL-12p70 and IL-6, but increased IL-10, in 354 
line with B cell–DC interactions noted previously[32]. B cells, activated to produce IL-10 by 355 
Leishmania major infection, induced suppression of IL-12 production by DCs[33]. Similarly, 356 
 17 
CpG-activated neonatal B cells were able to suppress IL-12 production by neonatal dendritic 357 
cells[34]. Direct B cell-DC interaction has been shown using B cell deficient (µMT-/-) mice, 358 
which produce higher levels of IL-12p70 from DCs compared to wild-type animals[35]. 359 
Furthermore, it is known that DCs cultured with IL-10 can shift from a Th1 pathway by 360 
reducing IL-12 secretion[21] and IL-10 can also affect DC antigen presentation[36]. It is 361 
conceivable that the reduction of MHC II expression on BM-DC by IL-10 producing B cells 362 
in our study could impact antigen presentation from DCs to CD4 T cells, leading to 363 
suboptimal CD4 T cell activation. 364 
It is clear that TLR4-activated NOD B cells operate directly on BM-DCs to inhibit CD8 T 365 
cell activation. We find that B cell-DC contact also amplifies B cell secretion of IL-10, which 366 
is exaggerated in the presence of IFNg-producing CD8 T cells. Our finding is consonant with 367 
a previous study suggesting that inflammatory cytokines can increase IL-10 production from 368 
Breg cells[37]. However, we also find IL-10 alone is not sufficient to inhibit BM-DC induced 369 
CD8 T cell proliferation, suggesting a contact-dependent change in BM-DCs upon initial 370 
engagement with B cells. Furthermore, if this initial contact-dependent change is reciprocal, 371 
or if CD45RBhiCD11clow DCs have any reverse effect on B cells is not yet understood. 372 
In this study, we also demonstrate an IL-10 dependent induction of CD45RB+CD11clo BM-373 
DCs, a distinct subset of tolerogenic CD45RBhiCD11clow DCs[38], which were induced with 374 
LPS-stimulated B cells more efficiently from protected NOD mice. A previous study 375 
suggests that a similar tolerogenic DC population produces IL-27 and promotes T cell 376 
tolerance mediated via IL-10[24]. Interestingly, this population can be induced with galectin-377 
1[24] which has recently been described to be required for regulatory B cell function[39]. 378 
Whether this mechanism is involved in the induction of CD45RB+CD11clo tolerogenic DC 379 
population by B cells in our study is for future investigation.  380 
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Our results are in line with the findings in human B cell-DC interactions, where human B 381 
cells influence the differentiation of DCs[40-42]. B cells activated by CD40 and TLR9 can 382 
also restrict monocytes from developing into mature DCs and reduce the expression of 383 
activation molecules and cytokine production by DCs[40]. Similarly, B cells activated via 384 
BCR signalling can induce DC maturation, which then drives differentiation of CD4 T cells 385 
to Th2 cells[42]. Again, this maturation is dependent on B cell–DC cell contact and reliant on 386 
B cell factors such as BAFFR (B cell activating factor receptor), TACI (transmembrane and 387 
calcium-modulating cyclophilin ligand interactor) and CD69[42]. It is clear that there is 388 
important cross-talk between B cells and DCs, and this is dependent on which signals B cells 389 
receive[41].  Our results suggest that the cross-talk between B cells and DCs is mutually 390 
modulated and both cell contact dependent and independent.   391 
In summary, we have found that B cells play a novel role in the natural protection of diabetes 392 
in NOD mice. B cells from protected NOD mice are high IL-10 producers, and suppress the 393 
activation status of BM-DCs, which in turn control pathogenic CD8 T cells. In contrast, the B 394 
cells from the non-protected diabetic NOD mice have reduced IL-10 expression, especially 395 
when activated via CD40, and weak suppressive function. Interestingly and importantly, if B 396 
cells from the non-protected diabetic mice are stimulated through innate immune signalling 397 
pathways, in particular TLR4 (LPS), these B cells have the capacity to produce IL-10 and 398 
immune suppressive function is restored. This alteration of suppressive B cell function under 399 
innate immune activation or inflammatory conditions may contribute to the dysregulation or 400 
abnormalities in DC populations found in individuals with type 1 diabetes[43]. Our study, 401 
thus, may point to a possible therapeutic target for future investigation.402 
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Methods 403 
Mice. 404 
NOD/Caj mice, originally from Yale University, were bred in-house at Cardiff University. 405 
The G9Cα-/-NOD mice were bred in-house at Cardiff University as previously described[20]. 406 
NOD TLR4-/- mice were bred in-house at Yale University. NOD.PI2tg mice, with transgenic 407 
overexpression of PI2 on the MHC class II promotor, were kindly provided by Prof. L 408 
Harrison and Dr. A. Lew. B6g7 were bred in-house at Cardiff University.  NOD.129P2(Cg)-409 
Il10tm1Cgn/DvsJ (IL-10KO) were bred in house at Yale University. Mice were maintained at 410 
Cardiff or Yale Universities in specific pathogen-free isolators or scantainers. All animals 411 
received water and food ad libitum, and were housed in a 12h dark/light cycle. The animal 412 
experiments were conducted in accordance with United Kingdom Animals (Scientific 413 
Procedures) Act, 1986 and associated guidelines. 414 
Diabetes Incidence. Mice were monitored weekly for glycosuria (Bayer Diastix) from 12 415 
weeks of age and when blood glucose levels were greater than 13.9mmol/L were diagnosed 416 
as diabetic. NOD mice that were 35 weeks of age or older and had never tested positive for 417 
glycosuria, and had blood glucose less than 13.9mmol/L were considered to be protected 418 
from diabetes, as the incidence of diabetes after this age is very low. 419 
Reagents.  420 
InvivoMab anti-mouse IL-10R (CD210) and InvivoMab rat IgG1 isotype control, anti-CD3 421 
(clone 2C11) and anti-CD28 (clone 37.51) were all purchased from Bioexcell. Recombinant 422 
IL-10 was purchased from Miltenyi Biotec. 423 
Cell preparation 424 
Bone marrow (BM-DCs) cells were flushed out from the hind legs (femur and tibia) and 425 
cultured with granulocyte macrophage colony stimulating factor (GM-CSF) at 1.5ng/ml and 426 
stimulated overnight with LPS (Sigma) at 1µg/ml before co-culture set up. Whole 427 
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splenocytes or freshly isolated splenic B cells, selected using B cell isolation kit (Miltenyi), 428 
were either seeded at 1x106/ml in a 24-well plate (for phenotyping) or 5x106 cells/ml in a 6- 429 
well plate (for co-cultures), and left either unstimulated or stimulated with 5µg/ml 430 
lipopolysaccharide (LPS), 5µg/ml anti-CD40 (Bioexcell) or 0.5µg/ml CPG (Eurofins MWG) 431 
for 24hrs before harvesting for further assays. CD8 T cells were negatively selected with 432 
CD8 T cell isolation kit (Miltenyi). Purity for all cell sorting was >95%.  433 
B cell: DC co-cultures 434 
NOD.PI2tg BM-DCs that were stimulated with LPS, were cultured either alone or with B 435 
cells, unstimulated or stimulated with various stimuli at a ratio of 1:3 (DC: B cell), and 436 
cultured in a 24-well plate for 3 days. For transwell experiments, B cells and DCs were 437 
separated by a 0.4µM membrane (Corning), with DCs placed in the bottom chamber, and 438 
unstimulated/stimulated NOD B cells placed in the top chamber. For DCs cultured with 439 
various NOD B cell supernatants, supernatants were centrifuged to ensure cell removal 440 
before the addition to 4x105 DCs (1ml per well). After 3 days, assays were analyzed by flow 441 
cytometry. 442 
B cell: DC: CD8 co-cultures 443 
NOD.PI2tg BM-DCs stimulated with LPS were cultured with freshly isolated G9Ca-/- CD8 T 444 
cells, with or without unstimulated or stimulated NOD or TLR4-/- B cells, at a ratio of 1:2:7 445 
(CD8: DC: B cell) for 3 days. G9Ca-/- CD8 T cells were labelled with 0.5µmol/L CFDA-SE 446 
(CFSE) (Invitrogen), before culture set up. For transwell experiments (Corning), 0.4µM 447 
membranes separated B cells from BM-DCs and CD8 T cells with unstimulated/stimulated B 448 
cells placed in the top chamber and BM-DCs and CD8 T cell mixed culture in the bottom. 449 
For anti-IL-10R blocking experiments 10µg/ml of anti-IL-10R or isotype was added for the 450 
3-day culture. 4x105 NOD.PI2tg BM-DCs were also cultured with recombinant IL-10 451 
(Miltenyi Biotech) alone at increasing concentrations. Plate-bound anti-CD3/CD28 (0.1µg/ml 452 
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anti-CD3, 1ug/ml anti-CD28) was coated on a 48 well plate overnight at 4°C, washed with 453 
PBS, before plating G9Ca-/- CD8 T cells labelled with CFDA-SE and cultured with or 454 
without NOD B cells from different stimulations. After 3 days, the assays were analysed by 455 
flow cytometry. 456 
Flow cytometry 457 
Single cell suspensions were incubated with TruStain (anti-mouse CD16/32 [Biolegend]) for 458 
10min at 4°C, followed by fluorochrome-conjugated mAbs against cell surface markers for 459 
30min at 4°C. Multi-parameter flow cytometry was carried out using mAbs: CD8 PE594 (53-460 
6.7), CD19 AF700 (6D5) CD11b APC or BV421 (M1/70), CD11c Pe-Cy7 (N418), MHC I 461 
PE (SF1-1.1), MHC II FITC (10-3-6), CD80 BV650 (16-10A1), CD86 Pe-Cy7 or AF700 462 
(PO3), CD44 BV711 (IM7), PD-L1 APC (10F-962), OX-40L PeCy7 (RM134), CD69 463 
BV510 (H1-2F3), CD45RB PerCPCy5.5 (C363-16.7) all from Biolegend. APC-Cy7 (1D3) 464 
and CD11c PerCPCy5.5 (N418) were purchased from eBioscience and BAFFR BV786 465 
(7H22-E16) was purchased from BD Biosciences. Cells were also stained with live/dead 466 
exclusion 605 (Invitrogen) or 780 (eBioscience). For intracellular cytokine analysis, 467 
splenocytes were either unstimulated or stimulated for 24hrs. Three hrs before antibody 468 
staining, PMA (50ng/ml) and ionomycin (500ng/ml) and monensin (3µg/ml) (all from 469 
Sigma-Aldrich) were added to the cells. Fc receptors were blocked using TruStain and after 470 
extracellular staining, cells were fixed using fixation/permeabilisation kit according to the 471 
manufacturer’s instructions (BD Biosciences), and subsequently stained for intracellular 472 
cytokines or with appropriate isotype controls. Cells were acquired on LSRFortessa (FACS 473 
Diva software) and analysis was performed using Flowjo software (Treestar).  474 
Cytokine assays 475 
Supernatants were taken from cell culture assays at the 3-day endpoint to analyze IL-10, IL-476 
12p70, MIP1β, IFNg and IL-6. Cytokines IL-10, IL-12p70, IFNg and IL-6 were measured by 477 
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the Meso Scale Discovery (MSD) system and MIP1β measured by ELISA (R&D systems). 478 
MSD was performed according to the manufacturer’s (Meso Scale Diagnostics, LLC.) 479 
instructions and detected using MSD Sector Imager 6000. MIP1β ELISA was run according 480 
to the manufacturer’s instructions (R&D systems). 481 
Statistical analysis.  482 
Statistical analysis was performed using GraphPad Prism (GraphPad Software, San Diego, 483 
CA). Significance was determined by One-way ANOVA followed by a Dunn’s multiple 484 
comparison or a Two-way ANOVA followed by a Bonferroni post-test for more than two 485 
variables, and a Mann-Whitney U test was performed for only two variables. Data were 486 
considered significant at p<0.05.487 
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Figure 1. Phenotypic analysis of B cells. Splenic B cells from protected (>35weeks old) and 627 
diabetic NOD mice were left unstimulated (BUS; white circle) or stimulated with LPS (BLPS; 628 
black square), anti-CD40 (BaCD40; dark grey triangle) or CPG (BCPG; light grey diamond) for 629 
24hrs before analysis for surface markers and cytokine production. (a) Isolated B cells were 630 
analysed for various surface markers. Representative flow cytometric plots (left) and graphical 631 
summary (right). (b) Representative flow cytometric plots for intracytoplasmic IL-6 and IL-10 632 
staining in total splenic B cells. Representative flow cytometric plots (top), graphical summary 633 
(bottom) (c) Graphical summary of intracytoplasmic (top) and secreted IL-10 (bottom) (d) 634 
Graphical summary of intracytoplasmic (top) and secreted IL-6 (bottom). Cytokines were 635 
measured by MSD. Black line represents the median value. B cells were gated on live CD19+ 636 
cells. Data represent at least 4 independent experiments. ns; non-significant, +P<0.05, 637 
++P<0.01, +++P<0.001, versus BUS (two-way ANOVA). *P<0.05, **P<0.01, ***P<0.001, 638 
protected versus diabetic (two-way ANOVA).  639 
Figure 2. LPS-stimulated B cells suppress insulin-specific CD8 T cells. NOD.PI2tg BM-DCs, 640 
CFSE-labelled G9Ca-/- CD8 T cells and splenic B cells that were unstimulated (BUS; white 641 
bar) or stimulated with one of LPS (BLPS; black bar), anti-CD40 (BaCD40; dark grey bar) or 642 
CPG (BCPG; light grey bar), from protected or diabetic NOD mice, were co-cultured for 3 643 
days before being examined by flow cytometry. CD8 T cells were gated on CD11c-CD11b-644 
CD19-CD8+ cells. (a) Co-culture set up and experimental design. (b) Live DC percentages 645 
(CD11c+CD11b+), **P<0.01, ***P<0.001, versus control (DC+CD8 alone, patterned bar) 646 
(one-way ANOVA) (c, d, e) CD8 T cell proliferation from B cell cultures; (c) CFSE 647 
representative flow plots and (d) graphical representation and (e) proliferation index. (f, g) 648 
CD44 surface staining on CD8 T cells (f) Representative flow plots and (g) graphical 649 
summary (h) ELISA of MIP1b cytokine levels in supernatants of cultures. (i) NOD.PI2tg BM-650 
DCs, G9Ca-/- CD8 T cells co-cultured with splenic B cells from TLR4KO mice, showing 651 
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(left) CD8 T cell proliferation by CFSE dilution, and (right) CD44 surface staining on CD8 T 652 
cells. In d-h, data were normalised to control (DC+CD8 alone). (j) G9Ca-/- CD8 T cell 653 
proliferation from plate-bound anti-CD3/anti-CD28 (0.1µg/ml, 1µg/ml respectively), cultured 654 
with unstimulated or stimulated B cells from protected or diabetic NOD mice. Data shown 655 
are mean ± SEM and represent at least 3 independent experiments. *P<0.05, **P<0.01, 656 
***P<0.001 versus BUS (two-way ANOVA). 657 
Figure 3. IL-10 partially mediates insulin-specific CD8 T cell suppression. (a, b) NOD.PI2tg 658 
BM-DCs, G9Ca-/- CD8 T cells and unstimulated (BUS) or B cells stimulated with LPS (BLPS) 659 
or anti-CD40 (BaCD40) from protected or diabetic NOD mice, were co-cultured for 3 days. (a) 660 
cytokine levels in B cell cultures; IL-10; dotted line represents baseline from CD8+DC 661 
control culture (124±25.4pg/ml); **P<0.01, ***P<0.001 (two-way ANOVA) (b) IL-10 662 
cytokine levels from protected or diabetic NOD B cell cultures, either plated alone or with 663 
NOD.PI2tg DCs and G9Ca-/- CD8 T cells (B+DC+CD8); *P<0.05, **P<0.01, ***P<0.001 664 
(Mann-Whitney U test); horizontal line represents the median value. (c) Unstimulated (BUS) 665 
or B cells stimulated with LPS (BLPS) or anti-CD40 (BaCD40) from protected, diabetic or IL-666 
10KO NOD mice, were co-cultured with BM-DCs from either NOD.PI2tg or IL-10KO mice 667 
for 3 days before IL-10 was measured. Dotted line (NOD.PI2tg) and dashed line (IL-10KO) 668 
represents baseline from DC alone cultures (347±34.6pg/ml; 218.2±69.2 respectively). (d, e, 669 
f) Unstimulated (BUS) or stimulated B cells either with LPS (BLPS) or anti-CD40 (BaCD40) 670 
from protected and diabetic NOD mice, treated with either isotype control (control), or anti-671 
IL-10 receptor (anti-IL-10R) or IL-10KO mice were cultured with NOD.PI2tg BM-DCs, 672 
G9Ca-/- CD8 T cells and investigated for (c) CD8 T cell proliferation (d) CD44 expression on 673 
CD8 T cells (e) CD80 expression on NOD.PI2tg DCs. Data were normalised to control 674 
(DC+CD8 alone, dotted line) *P<0.05, **P<0.01, ***P<0.001 (two-way ANOVA). Data 675 
shown are mean ± SEM. Data shown represent at least 3 independent experiments.  676 
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Figure 4. B cell: DC cell contact suppresses CD8 T cell proliferation and activation. 677 
Activated NOD.PI2tg  BM-DCs and unstimulated (BUS) or B cells stimulated with either LPS 678 
(BLPS) and anti-CD40 (BaCD40) from protected or diabetic NOD mice were cultured with 679 
G9Ca-/- CD8 T cells (a-d) or without G9Ca-/- CD8 T cells (e, f) for 3 days before analyses. B 680 
cells were cultured either in contact (Cont) or separated from BM-DCs +/- CD8 T cells in 681 
transwells (Trans). (a, b) flow cytometric analyses on CD8 T cells. Representative plots (left) 682 
and summary graphs (right) on (a) CFSE dilution illustrating proliferation (b) CD44 surface 683 
expression. Data were normalised to DC+CD8 alone control cultures (dotted line). (c, e) 684 
Supernatants from protected and diabetic NOD DC-B cell-CD8 T cell co-cultures (c) IFNg 685 
(e) IL-10. (d, f) Supernatants from protected and diabetic NOD DC-B cell co-cultures (d) 686 
IFNg (f) IL-10. Data shown are mean ± SEM. *P<0.05, **P<0.01, ***P<0.001, versus BUS 687 
(two-way ANOVA); +P<0.05, ++P<0.01, Cont vs Trans (two-way ANOVA). Data represent at 688 
least 3 independent experiments. 689 
Figure 5. BLPS have lasting tolerogenic effects on mature BM-DCs. Activated NOD.PI2tg  690 
BM-DCs and unstimulated (BUS) or B cells stimulated with either LPS (BLPS) and anti-CD40, 691 
(BaCD40) from protected or diabetic NOD mice, were co-cultured for 3 days before being 692 
removed, and remaining NOD.PI2tg  BM-DCs were cultured with G9Ca-/- CD8 T cells for 3 693 
days, before being assessed by flow cytometry. (a) Experimental set up; (b) CFSE dilution 694 
illustrating CD8 T cell proliferation; (c) CD44 surface expression on CD8 T cells. CD8 T 695 
cells were gated on live CD11b-CD11c-CD19-CD8+ cells. (d) Cytokine analysis of 696 
supernatants for IL-10 (left), IL-12p70 (middle), IL-6 (right). Control (chequered bar) 697 
represents DCs not cultured with B cells, prior to the addition of CD8 T cells. Data shown are 698 
mean ± SEM. *P<0.05, **P<0.01, two way ANOVA. Data represent 3 independent 699 
experiments.  700 
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Figure 6. B cells modulate mature DC activation. Mature NOD.PI2tg  BM-DCs and 701 
unstimulated (BUS) or B cells stimulated with either LPS (BLPS) and anti-CD40 (BaCD40) from 702 
protected or diabetic NOD mice were co-cultured for 3 days before analysis (a, b) DC-B cell 703 
co-cultures were either cultured together in contact (Cont) or in a transwell plate (Trans) or 704 
BM-DCs were treated with supernatants from B cells either unstimulated or different stimuli 705 
(24hrs prior to co-culture) (Sup), and mature NOD.PI2tg DCs analysed for various surface 706 
markers. (a) Representative plots and (b) combined graphical data. Dotted line represents DC 707 
control (no B cells). All data were normalized to DC control cultures. *P<0.05, **P<0.01, 708 
***P<0.001, cont vs trans vs sup (two-way ANOVA); +P<0.05, ++P<0.01, +++P<0.001, versus 709 
BUS (two-way ANOVA). Data shown are mean ± SEM. Data represent at least 3 independent 710 
experiments.  711 
Figure 7. BLPS induces a CD45RB+CD11clo tolerogenic DC population. Activated NOD.PI2tg  712 
BM-DCs and unstimulated (BUS; white circle) or B cells stimulated with either LPS (BLPS; 713 
black square) and anti-CD40 (BaCD40; grey triangle) from protected or diabetic or IL-10KO 714 
NOD mice were co-cultured for 3 days before analysis. (a) representative plots (left) and 715 
summary graph (right) of CD45RB+ DC (gated on Live CD11c+CD11b+) populations, dotted 716 
line represents DC alone (control DC). Horizontal line represents median value b) 717 
representative flow plots for CD11c, CD80 and CD86 expression on CD45RB+ (solid line) 718 
and CD45RB- (dashed line) populations. (c) CD11c, CD80 and CD86 summary graphs on 719 
CD45RB+ and CD45RB- populations from pooled protected and diabetic NOD mice. Data 720 
shown are mean ± SEM. Data shown represent 3 independent experiments. *P<0.05, 721 
**P<0.01, ***P<0.001, two-way ANOVA. 722 
Figure 8. Schematic summary of B cell-directed CD8 T cell suppression in the context of type 723 
1 diabetes. 1. B cells from protected NOD mice stimulated via TLR4 or anti-CD40 express 724 
substantial intracellular IL-10 but only secrete IL-10 with TLR4 stimulation. 2. B cells from 725 
 31 
diabetic NOD mice express reduced intracellular IL-10 when stimulated via TLR4 and lack 726 
IL-10 expression with anti-CD40 stimulation, but can secrete IL-10 with TLR4 stimulation. 727 
3. (a) BM-DCs engage with TLR4 activated B cells, from protected NOD mice (b) On initial 728 
engagement a possible reciprocal contact-mediated process, inducing an altered BM-DC in 729 
order to generate an IL-10 feedback loop and tolBM-DC induction by IL-10 (dotted arrows) 730 
(c) B cell: BM-DC contact augments IL-10 production from B cells, creating a feedback loop 731 
as shown by solid black arrows. (d) B cell: BM-DC contact and IL-10 secretion induces a 732 
deactivated tolerogenic BM-DC population (tolBM-DCs). (e) tolerogenic deactivated BM-733 
DCs suppress pathogenic CD8 T cells (f) Effect of tolBM-DCs on B cells, after induction, is 734 
still unknown (dashed arrow). 4. B cells from diabetic NOD mice, have a diminished 735 
response to contact with BM-DCs, which results in fewer deactivated tolBM-DCs. 5. In the 736 
presence of CD8 T cells and proinflammatory cytokines i.e. IFNg, B cells, stimulated with 737 
LPS, from diabetic NOD mice, in contact with BM-DCs, amplify their IL-10 response and 738 
induce CD8 T cell suppression as effectively as B cells from protected NOD mice. 739 
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Supplementary figure 1. Age matched B6G7 mice have little IL-10 potential. Splenic B cells 
from B6G7 mice, aged either 10-17 weeks or more than 35 weeks, were left unstimulated 
(BUS) or stimulated with LPS (BLPS), anti-CD40 (BaCD40) or CPG (BCPG) for 24hrs before (a) 
being analysed for IL-10 (left) and IL-6 (right) potential by intracytoplasmic staining. B cells 
were gated on live CD19+ cells.  The horizontal line represents the median value. P<0.05, 
**P<0.01, ***P<0.001; two-way ANOVA. Data represent at least two independent 
experiments. 
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Supplementary figure 2. CD8 T cell suppression is not due to increased CD8 T cell death. 
NOD.PI2tg BM-DCs, CFSE-labelled G9Ca-/- CD8 T cells and splenic B cells that were 
unstimulated (BUS; white bar) or stimulated with one of LPS (BLPS; black bar), anti-CD40 
(BaCD40; dark grey bar) or CPG (BCPG; light grey bar), from protected or diabetic NOD mice, 
were co-cultured for 3 days before being examined by flow cytometry. CD8 T cells were 
gated on CD11c-CD11b-CD19-CD8+ cells. (a) CD8 T cell proliferation in controls (DC+CD8 
T cells alone) is shown for all assays. Line represents the median value. (b) Graph shows 
viable live CD8 T Cells. The control was DC+CD8 alone, shown as the patterned bar. Data 
shown are mean ± SEM (Data represent at least 3 independent experiments). 
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Supplementary figure 3. B cells from B6g7do not suppress insulin-specific CD8 T cells 
NOD.PI2tg BM-DCs, CFSE-labelled G9Ca-/- CD8 T cells and splenic B cells that were 
unstimulated (BUS; white bar) or stimulated with one of LPS (BLPS; black bar), anti-CD40 
(BaCD40; dark grey bar) or CPG (BCPG; light grey bar), from B6g7 (a, b) or protected or diabetic 
NOD mice (c), were co-cultured for 3 days. (a) CD8 T cell proliferation, normalised to 
control (DC+CD8 alone; dotted line). CD8 T cells were gated on CD11c-CD11b-CD19-CD8+ 
cells. (b) Supernatant detection of IL-10 cytokine in culture medium. (c) Supernatant 
detection of IL-6 cytokine in culture medium, dotted line represents DC+CD8 alone. Data 
shown in (a, b) for BaCD40 and BCPG cultures represent one experiment. Data shown in (a, b) 
for BUS and BLPS  and (c) represent 3 independent experiments. 
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Supplementary figure 4. IL-10 affects co-stimulatory markers on mature BM-DCs. (a) 
NOD.PI2tg BM-DCs were cultured either alone (chequered bar) or with splenic B cells that 
were unstimulated (BUS; white bar) or stimulated with LPS (BLPS; black bar) or anti-CD40 
(BaCD40; dark grey bar) from IL-10KO B cells, for 3 days before measurement of IL-10, 
*P<0.05, one-way ANOVA (b, c, d) NOD.PI2tg BM-DCs and CFSE-labelled G9Ca-/- CD8 T 
cells were cultured for 3 days and CD8 T cells were gated on live CD11c-CD11b-CD8+ cells; 
(b) DC and CD8 T cells cultured with or without increasing concentrations of recombinant 
IL-10 and the graph shows CD8 T cell proliferation; (c) DC and CD8 T cells cultured with 
10µg/ml anti-IL-10R and the graph shows CD8 T cell proliferation (left) and CD8+CD44+ 
surface expression (right); (d) DC and CD8 T cells cultured with increasing concentrations of 
recombinant IL-10 and the graph shows CD86 and CD80 expression on BMDCs, gated on 
live CD8-CD11c+CD11b+ cells. (e) NOD.PI2tg BM-DCs, G9Ca-/- CD8 T cells and 
unstimulated (BUS) or B cells, stimulated with either LPS (BLPS) or aCD40 (BaCD40) from 
protected/diabetic NOD mice, were either treated with isotype control (control) or 10µg/ml 
anti-IL-10R (anti-IL10R), or IL-10KO B cells, and co-cultured for 3 days.  The cultures were 
analyzed for CD86 on CD8-CD19-CD11c+CD11b+ BM-DCs. Data were normalised to control 
(DC+CD8 alone, dotted line). Data shown are mean ± SEM. Data represent at least 3 
independent experiments.
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Supplementary figure 5. Stimulated B cells can regulate MHC II expression on mature BM-
DCs independent of cell contact. Activated NOD.PI2tg  BM-DCs and unstimulated (BUS) or B 
cells stimulated with either LPS (BLPS) and aCD40 (BaCD40) from protected or diabetic NOD 
mice were co-cultured for 3 days before analysis. (a) Live DC percentages from DC-B cell 
cultures; (b) MHC II (left) and CD40 (right) expression on live CD19-CD11b+CD11c+ 
BMDCs; (c) DC-B cell co-cultures were either cultured together in contact (Cont) or in a 
transwell plate (Trans) and analysed for MHC II and CD40 expression on live CD19-
CD11b+CD11c+ BMDCs. **P<0.01, versus BUS (two-way ANOVA), +P<0.05, versus cont vs 
trans (two-way ANOVA). Dotted line represents DC control (no B cells) (DCCTL). Data were 
normalized to DC control. Data shown are mean ± SEM. Data represent at least 3 
independent experiments.  
 
 
 
a
b
Cont Trans Cont Trans
Cont Trans Cont Trans
BUS BLPS BCD40
c Protected Diabetic
